BPC-157 + TB-500 · recovery + tissue repair
The most common research-peptide recovery stack. BPC-157 for cytoprotection + angiogenesis; TB-500 for cell migration + actin remodeling. Combined for tendon, ligament, muscle injury.
Mechanism rationale
BPC-157 (a 15-amino-acid synthetic gastric peptide) and TB-500 (a synthetic fragment of thymosin beta-4) work on overlapping but distinct healing pathways. BPC-157 promotes angiogenesis (new blood vessel formation) and modulates the nitric oxide system in injured tissue; TB-500 promotes cell migration and actin polymerization, which matters for cells moving into the injury site. The community framing is that BPC-157 builds the supply chain (vessels), TB-500 moves the workforce (cells). The pairing is universal in research-peptide recovery protocols and largely uncontested as community practice.
Standard dose schedule
Loading phase: 250 mcg BPC-157 sub-q daily + 2 mg TB-500 sub-q twice weekly for 4 to 6 weeks. Maintenance: same BPC-157 dose at 3-4x weekly + 2 mg TB-500 once weekly for another 4 to 6 weeks. Both can be injected near the injury site (peri-injury) or systemically; TB-500's longer half-life (estimated tens of hours) makes systemic dosing equally effective vs BPC-157's shorter half-life favouring local. Reconstitution: 5 mg vials of each in 5 mL bacteriostatic water (1 mg/mL).
Not medical advice. Reconstitution math at /tools/reconstitution-calculator.
The honest read
Animal studies on each compound individually are reasonable; pre-clinical data on the combination is sparse. No formal human trials of the stack exist. The community evidence base is large (thousands of self-reports) but uncontrolled; selection bias is heavy because users with negative experiences often disappear from the conversation. The honest read: this stack works for many users in subjective recovery improvement, but the 'works' is not separable from placebo + spontaneous healing in most reports.
What both compounds share
Both compounds affect cell proliferation pathways. BPC-157 promotes angiogenesis; TB-500 promotes cell migration. Both are mechanisms cancer cells exploit. Anyone with active or recent cancer should not run this stack without oncology consultation. Both compounds are banned by WADA in competitive sport. Long-term safety data does not exist for either. Pregnancy + breastfeeding off-limits.
Related Panya answers
BPC-157 if your injury is tendon, ligament, or gut. TB-500 if it's soft tissue (muscle tear, joint capsule). Stacking both is the community default but the human evidence does not ...
Standard community recovery stack: 250 mcg BPC-157 sub-q daily plus 2 mg TB-500 sub-q twice weekly for 4 to 6 weeks loading, then BPC-157 at 3 to 4 times weekly plus TB-500 once we...
If you have a specific tendon or joint injury that has plateaued on conservative management and you accept that the human evidence is thin, then yes, on a defined 4 to 6 week cycle...
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.
Last reviewed 2026-04-29. Stack pages refresh when literature, supply, or community practice shifts materially. Email partner@panya.health if you spot something we have wrong.